UK markets closed
  • FTSE 100

    7,208.81
    +188.36 (+2.68%)
     
  • FTSE 250

    19,123.71
    +430.73 (+2.30%)
     
  • AIM

    896.27
    +10.41 (+1.18%)
     
  • GBP/EUR

    1.1618
    -0.0028 (-0.24%)
     
  • GBP/USD

    1.2270
    +0.0009 (+0.07%)
     
  • BTC-GBP

    17,165.03
    -24.64 (-0.14%)
     
  • CMC Crypto 200

    462.12
    +8.22 (+1.81%)
     
  • S&P 500

    3,911.74
    +116.01 (+3.06%)
     
  • DOW

    31,500.68
    +823.32 (+2.68%)
     
  • CRUDE OIL

    107.06
    +2.79 (+2.68%)
     
  • GOLD FUTURES

    1,828.10
    -1.70 (-0.09%)
     
  • NIKKEI 225

    26,491.97
    +320.72 (+1.23%)
     
  • HANG SENG

    21,719.06
    +445.19 (+2.09%)
     
  • DAX

    13,118.13
    +205.54 (+1.59%)
     
  • CAC 40

    6,073.35
    +190.02 (+3.23%)
     

COSMO ANNOUNCES FULL-YEAR RESULTS 2021;CONFIRMS BEATING GUIDANCE

·8-min read

Cosmo Pharmaceuticals N.V. / Key word(s): Annual Results

23-March-2022 / 06:00 GMT/BST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.

Ad hoc announcement pursuant to Art. 53 LR

Dublin, Ireland - 23 March 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) ('Cosmo') reports full-year 2021 results for the year ended 31 December 2021, confirms beating guidance, and, as previously announced, proposes a dividend of €0.95 per share at the next AGM on 27 May 2022.

Business Highlights:

  • FDA approved GI Genius(TM), the first-to-market device that uses artificial intelligence (AI) to assist clinicians in the detection of lesions in the colon in real time during a colonoscopy.

  • DETECT study showed AI assistance using GI Genius(TM) reduces missed polyp rate by over 50% on initial colonoscopy.

  • Signed licence and supply agreement between Cassiopea S.p.A. and Sun Pharmaceutical Industries for Winlevi(R) in the U.S. and Canada.

  • Winlevi(R) launched by Sun Pharmaceutical Industries in the U.S. in November 2021.

  • Cosmo launched and successfully closed public exchange offer to acquire Cassiopea S.p.A.

  • Licensed EU rights (plus Switzerland, U.K., EEA countries and Mexico) for Lumeblue(R) to Alfasigma S.p.A.

  • Announced successful outcome of phase II proof of concept (POC) clinical trial of Rifamycin SV MMX(R) 600 mg in irritable bowel syndrome with diarrhoea (IBS-D).

Financial Highlights:

  • Revenue increased 6.9% to €65.1 million compared to €60.9 million in 2020.

  • EBITDA increased 42.7% to €18.5 million compared to €12.9 million in 2020.

  • Operating profit increased 60.9% to €11.1 million compared to €6.9 million in 2020.

  • Profit after tax of €21.7 million, including share of Cassiopea gain €17.8 million, compared with a loss after tax of €7.9 million in 2020.

  • Net cashflow from operating activities of €12.6 million compared to €13.0 million in 2020.

  • Cash and fund investments of €222.2 million compared to €212.9 million at 31 December 2020.

  • Equity attributable to owners of the Company €505.3m at 31 December 2021 vs €400.1m at 31 December 2020.

  • A dividend of €0.95 per share will be proposed at the next AGM on May 27, 2022.

Key figures:

EUR /000

2021

2020

Income statement

Revenues

65,074

60,949

Cost of sales

(32,977)

(27,617)

Gross profit

32,097

33,332

Other income

819

5,848

R&D costs

(11,357)

(13,597)

SG&A costs

(10,458)

(18,678)

Net operating expenses

(20,996)

(26,427)

Operating profit

11,101

6,905

Net financial expense

(4,292)

(8,895)

Share of result of associates

17,753

(4,941)

Loss on remeasurement to fair value of pre-existing interest in an acquiree

(559)

-

Profit / (Loss) before taxes

24,003

(6,931)

Profit / (Loss) after taxes for the period

21,673

(7,901)

Statement of financial position

2021

2020

Non-current assets

529,713

343,293

Cash and cash equivalents

198,560

185,937

Other current assets

77,289

66,931

Liabilities

292,884

196,036

Equity attributable to owners of the Company

505,276

400,125

Non-controlling interests

7,402

-

Equity ratio (%)

63.6%

67.1%

Shares

Weighted average number of shares

16,842,054

14,471,064

Earnings per share (in EUR)

1.287

(0.546)

Mauro Ajani, Chairman of Cosmo, said: 'I am very satisfied to see Cosmo's entering large markets while preserving its pioneering approach.'

Alessandro Della Chà, Chief Executive Officer, said: 'We entered 2021 with high expectations and we are pleased to report remarkable business achievements during yet another challenging year. Most importantly, Cosmo has shifted from niche markets to very large markets, thereby significantly increasing our revenue potential. We now have two new and very innovative products, GI Genius(TM) and Winlevi(R), in two major markets. We are tackling these opportunities with two very strong partners, Medtronic and Sun Pharma. GI Genius(TM) addresses the worldwide colonoscopy market of an estimated 60 million annual colonoscopy procedures, of which an estimated 19 million are carried out in the US which, in terms of volume, is second only to the blood test. Winlevi(R) addresses the acne market with the first new mechanism of action for the treatment of this condition in almost 40 years. Acne affects an estimated 640 million people worldwide and the market in the US is worth an estimated USD 5bn per annum just for prescription drugs alone. In the meantime, we have seen our legacy products continue to perform well notwithstanding the difficult environment due to the pandemic. Our results reflect our capabilities, execution mindset and commitment to long term relationships. We are progressing the replenishment of our development pipeline and our performance in 2021 is reflected in a positive cashflow from operations and in our strong balance sheet. Our year-end cash balance of €222.2 million provides us with the necessary financial flexibility to execute on our strategic priorities. We are thus confident about our 2022 outlook.'


Cosmo provided the following 2022 financial outlook:

  • Total revenues in the range of €90m - €100m vs €65.1m in 2021.

  • Operating profit in the range of €20m - €25m vs €11.1m in 2021.

Management updates:

Effective April 1, 2022, Mr. Luigi Longo, currently Cosmo's R&D Operations Manager, will be promoted to the role of Chief Scientific Officer (CSO).Mr. Longo, Italian (born 1979), began his career as an analytical laboratory scientist in Cosmo S.p.A. in June 2005. He continued his career in the R&D laboratory department and was appointed Scientific Project Manager in 2014. In this role, he collaborated with the CSO of Cosmo in the management of several R&D projects and contributed to the successful completion of several R&D development programs. Mr. Longo has a degree in chemistry and pharmaceutical technology from 'La Sapienza' University in Rome.

Further, the Company has hired Mr. Stefano Alvergna as Chief Medical Officer, effective April 1, 2022. Mr. Alvergna, Italian (born 1958), has 30 years of experience in R&D and clinical research on drugs and medical devices covering different roles in CROs and pharmaceutical companies. Prior to joining Cosmo Mr. Alvergna was responsible for Scientific Service and Corporate Medical Affairs at Fidia Farmaceutici. In his career he has planned and managed more than 200 clinical trials, supervising scientific activities and medical aspects from phase I to III in different therapeutical areas. He has a degree in Medicine and Surgery from the University of Bologna, where he specialized in Toxicology.

The Full-Year Report 2021 with further information was published today, 23 March 2022 at 07:00 am CET and is available for download at:

http://www.cosmopharmaceuticals.com/investor-relations/financial-reports

Live conference call and video webcast presentation:

Date:

Wednesday, 23 March 2022

Time:

2:00 pm CET


Webcast link: Chrome (recommended) or Firefox https://services.choruscall.com/mediaframe/webcast.html?webcastid=96saDCmZ

Please note that there is a function to type in your questions via webcast.

Via phone:

Participants wishing to ask verbal questions via phone, may call the following numbers below. To ensure prompt access, please call approximately ten minutes prior to the scheduled start of the call.

Switzerland / Europe

+41 (0) 58 310 50 00

United Kingdom

+44 (0) 207 107 06 13

United States

+1 (1) 631 570 56 13

Replay

The webcast, along with the presentation will be available online shortly after the event and accessible for three months.

Calendar

Annual General Meeting 2022

27 May 2022

Half-Year Results 2022

29 July 2022

About Cosmo Pharmaceuticals
Cosmo is a specialty pharmaceutical company focused on developing and commercialising products to treat selected gastrointestinal disorders and improve endoscopy quality measures through aiding the detection of colonic lesions. Cosmo has also developed medical devices for endoscopy and has recently entered into a partnership with Medtronic for the global distribution of GI Genius(TM) its artificial intelligence device for use in coloscopies and GI procedures. Cosmo has licensed Aemcolo(R) to Red Hill Biopharma Ltd. for the US and has licensed Relafalk(R) to Dr. Falk Gmbh for the EU and other countries. For additional information on Cosmo and its products please visit the Company's website: www.cosmopharma.com

Disclaimer
Some of the statements in this press release may be forward-looking statements or statements of future expectations based on currently available information. Such statements are naturally subject to risks and uncertainties. Factors such as the development of general economic conditions, future market conditions, unusual catastrophic loss events, changes in the capital markets and other circumstances may cause the actual events or results to be materially different from those anticipated by such statements. Cosmo does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of such statements. Therefore, in no case whatsoever will Cosmo and its affiliate companies be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or for any related damages.

Contact
Hazel Winchester
Head of Investor Relations
Cosmo Pharmaceuticals N.V.
Tel: +353 1 817 03 70
hwinchester@cosmopharma.com


End of ad hoc announcement

Language:

English

Company:

Cosmo Pharmaceuticals N.V.

Riverside 2, Sir John Rogerson's

Dublin 2 Dublin

Ireland

Phone:

+ 353 1 817 0370

E-mail:

info@cosmopharma.com

Internet:

https://www.cosmopharma.com/

ISIN:

NL0011832936

Listed:

SIX Swiss Exchange

EQS News ID:

1309241


 

End of Announcement

EQS News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting